Beijing Kawin Technology Share-Holding Co., Ltd. (SHA:688687)

Market Cap	6.02B
Revenue (ttm)	1.25B
Net Income (ttm)	145.89M
Shares Out	167.44M
EPS (ttm)	0.87
PE Ratio	41.32
Forward PE	35.77
Dividend	0.30 (0.83%)
Ex-Dividend Date	Jun 11, 2025

Volume	10,658,052
Average Volume	11,537,934
Open	34.90
Previous Close	35.20
Day's Range	34.90 - 36.85
52-Week Range	18.97 - 36.50
Beta	1.09
RSI	81.59
Earnings Date	Aug 15, 2025

About Paycor HCM

Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China. The company’s products include recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon Alfacon-2 Injection; and compound glycyrrhizin tablets, capsules, and injections, as well as pirfenidone tablets. The company was founded in 2008 and is based in Beijing, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 600
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688687

Financial Performance

In 2024, SHA:688687's revenue was 1.23 billion, a decrease of -12.87% compared to the previous year's 1.41 billion. Earnings were 142.37 million, an increase of 22.18%.